Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of "A." MSCI ESG Research provides MSCI ESG Ratings on global public and a few private companies on a scale of AAA (leader) to CCC (laggard), according to exposure to industry-specific ESG risks and the ability to manage those risks relative to peers. Learn more about MSCI ESG ratings here.
"In addition to the Prime status achieved from ISS ESG in May, the MSCI ESG Rating gives us confidence that our long-term commitment to ESG principles is being recognized as we build a vibrant, sustainable enterprise with the ultimate goal of delivering our important medicines to patients who need them," said Laurie Stelzer, Chief Financial Officer of Arena Pharmaceuticals. "We are proud to be recognized as not only a sustainable company, but also a sustainable investment."
The MSCI ESG Rating of "A" follows the release of Arena’s second annual ESG report in April 2021, outlining the Company’s long-term commitment to the betterment of society, focusing on patients, employees, the community, the environment, and shareholders.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done.
We are developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology and cardiology. Our pipeline includes four investigational medicines in eight indications and eleven ongoing or planned clinical trials. To fuel our growth, we are unlocking the value of our historical GPCR research with a sustainable discovery engine for broad portfolio expansion.
ARENA - Care More. Act Differently.
About MSCI ESG Research
MSCI ESG Research provides in-depth research, ratings and analysis of the environmental, social and governance-related business practices of thousands of companies worldwide, designed to provide critical insights that can help institutional investors identify risks and opportunities that traditional investment research may overlook.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as “long-term,” “commitment,” “goal,” “purpose,” “targeting,” and “planned,” and include, without limitation, statements about Arena's ESG initiatives, purpose, work, understanding, ideas, execution, portfolio, and discovery engine. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which was filed with the SEC on May 5, 2021. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Arena Pharmaceuticals, Inc.
Vice President, Investor Relations & Corporate Communications